CD34+ cell is an important surface marker of the hematopoietic stem/progenitor cells. "Positive selection" method in which this marker is adapted has been used to obtain highly purified CD34+ cells that play an important role in the study of the hematopoietic stem/progenitor cells. The transplantation of the bone marrow and peripheral blood stem cells that now generally applied is actually the transplantation of the mixture including the stem/progenitor cells and the mature cells of various lineages. The hematopoietic reconstitution needs only enough number of stem/progenitor cells and other fractions would even be harmful to transplantation. "Negative selection" method has been used to remove the non-stem/progenitor cells, but its effectiveness was usually not good and it could be harmful to the stem/progenitor cells. "Positive selection" method not only gets rid of the above flaw but also can be used to obtain high dose of purified CD34+ cells to meet clinical need for the stem/progenitor cells. The transplantation of CD34+ cells purified with clinical-grade Magnetic Activated Cell Sorting system, CliniMACS(Miltenyi Biotec /AmCell), has been proceeded in Europe and the preliminary study was successful (1). Since 1998, using CliniMACS system, we have purified CD34+ cells from 27 leukapheresis products which were separated with CS-3000 plus blood cell separator from 24 mobilized patients or normal donors. 21 patients have received transplants, of which 18 patients are eligible for preliminary evaluation.
3. Patients and methods
a) Donors and recipients
24 donors, including 15 males and 9 females ......
|
关闭窗口